The interim results of pharmaceutical listed companies are over 70%
Wind data show that as of July 26, according to the "industry classification, the two cities has 84 listed pharmaceutical companies issued interim results, disclosed progress has more than 84 companies, in addition to the one in uncertain, advance company number 63, xi ratio reached 75%. People in the industry said that the new health care system was introduced, the medical reform deepened, the policy was released and implemented into intensive period, and the entire pharmaceutical sector was differentiated. Among them, the benefit of the implementation of supply-side reform such as environmental inspection, the performance of some raw materials and pharmaceutical leading enterprises has increased significantly.
Supply-side reform pushed forward
Bureau of statistics data show that in January 2017, five months of pharmaceutical manufacturing main business income is 1.16171 trillion yuan, up 11.9% from a year earlier, the profit is 125.52 billion yuan, up 15.7% year on year, revenue and profit growth in 2016 during the same period increased 1.91 and 0.73% respectively. The steady growth of fundamentals reflects the steady growth of the pharmaceutical industry in the economic downturn.
At the lower end of the net profit growth, 54 companies achieved net profit growth year-on-year, with 16 companies reporting a year-on-year increase of more than 50 per cent, with 10 companies expected to double their performance.
In terms of the growth rate of the company, some raw materials and pharmaceutical leading enterprises have benefited from the decrease in supply of environmental protection and the production and marketing of major products.
Northeastern pharmaceuticals is currently at the top of the list. The company expects to achieve a net profit of 38 million yuan to 41 million yuan in the first half of the year, a year-on-year increase of 1106% to 115%. The company said that compared with the same period a year ago, the company's leading product, vitamin C, rose in price, while sales of long orders fell from the first quarter.
Garden creatures in the vitamin camp of northeastern pharmaceuticals also expect a surge in first-half results. The company expects to achieve a profit of 73 million yuan to 77 million yuan in the first half of the year, a year-on-year increase of 364-389%. The company said the big increase in performance was mainly due to a big increase in sales of cholesterol and 25-hydroxyl vitamin D3, which is the product of the company's initial public offering, which increased the company's profits. It is worth noting that investment institutions have long been optimistic about the company's performance and performance in 2017, and that many securities investment funds and cattle have been dormant since the end of 2016.
One of the traditional Chinese medicine taps has a good reputation. The company expects to achieve a net profit of about 72 million yuan in the first half of the year, a year-on-year increase of about 235%. Company said that during the reporting period, with the "good China" pregnancy activities such as market in full swing and the increase of advertising, the company's core subsidiary wide reputation far core business sectors - shanxi traditional Chinese medicine sales revenue to achieve rapid growth, growth of about 70% year-on-year, at the same time, the company further strengthen the cost control, making further improve profitability; Plus, the Shanxi Province wide reputation far on December 1, 2016 through the recognition of hi-tech enterprises, enterprise income tax shall be levied at a reduced rate of 15%, the composite made shanxi wide reputation far attributable to the parent company net profit year-on-year growth of 80% or so; In addition, compared with a year earlier, the company holds a wide reputation far in shanxi's stake to 96.03% from 55%, the company in 2017 semi-annual net profit attributable to shareholders of listed companies showed a sharp increase.
Focus on leading companies
Brokerage personage points out, although the pharmaceutical industry profit although steady growth, but in the "two votes" overweight, national drug regulatory and strengthening health reform under the background of the development of the pharmaceutical industry difficult speaking out of turn positive.
(RongFa god, medicine, and deal beida pharmaceutical industry, etc., the company said, because the company's products to be included in the medical insurance directory, gradually implement national health care around the negotiating price, reduction product is bigger, sales year-on-year decline.
Galaxy securities said that leading companies and innovative drug companies deserve attention. At present, the valuation level of the white horse stock in the domestic pharmaceutical industry is close to that of the international pharmaceutical giants, while the overall growth rate of the domestic market is higher than that of the international market. Domestic leading companies are more growth and long-term development with certainty. Secondly, innovative drug investment is the top priority of pharmaceutical investment. Globally, investment opportunities in the pharmaceutical industry are closely related to innovation, and it is recommended to focus on a-share related listed companies.
PgUp [1] [2] [3] PgDn
|
